Bukwang Pharmaceutical Co., Ltd.

KOSE:A003000 Stock Report

Market Cap: ₩316.3b

Bukwang Pharmaceutical Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of A003000?
Owner TypeNumber of SharesOwnership Percentage
Employee Share Scheme23,0860.0337%
Institutions2,055,1433%
Public Companies7,747,93411.3%
Individual Insiders13,103,26619.1%
General Public45,525,24266.5%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 18 shareholders own 33.5% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
11.3%
OCI Holdings Company Ltd.
7,747,934₩35.8b0%no data
10.3%
Dong-Yeon Kim
7,053,266₩32.6b0%no data
8.84%
Jeong Chang Su
6,050,000₩28.0b0%no data
1.96%
The Vanguard Group, Inc.
1,338,967₩6.2b0%no data
0.34%
Dimensional Fund Advisors LP
233,418₩1.1b0.03%no data
0.29%
Mirae Asset Global Investments Co., Ltd.
199,999₩924.0m99.3%no data
0.2%
Norges Bank Investment Management
136,324₩629.8m0%no data
0.096%
Charles Schwab Investment Management, Inc.
65,702₩303.5m0%no data
0.086%
State Street Global Advisors, Inc.
58,997₩272.6m1.11%no data
0.034%
Bukwang pharm. co., Ltd. Employee Stock Ownership Association
23,086₩106.6m0%no data
0.021%
American Century Investment Management Inc
14,621₩67.6m-0.03%no data
0.0036%
Samsung Asset Management Company, Ltd.
2,475₩11.4m0%no data
0.0035%
IBK Asset Management Co., Ltd.
2,367₩10.9m0%no data
0.0012%
Invesco Capital Management LLC
840₩3.9m0%no data
0.00098%
KB Asset Management Co., Ltd.
672₩3.1m0%no data
0.00057%
NH-Amundi Asset Management
393₩1.8m0%no data
0.00035%
Korea Investment Management Co., Ltd.
240₩1.1m0%no data
0.00019%
Consus Asset Management Co. Ltd.
128₩600.9k0%0.02%

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/27 08:07
End of Day Share Price 2024/12/27 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Bukwang Pharmaceutical Co., Ltd. is covered by 5 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jin Kyun LimIBK Securities Co. Ltd.
JongHoon LeeMirae Asset Securities Co., Ltd. (Pre-Merger)
Seung KimSamsung Securities Co. Ltd.